Preferred Label : Cisplatin;
NCIt synonyms : Cis-diammine-dichloroplatinum; Cis-platinum II; Cisplatina; Platinum Diamminodichloride; Peyrone's Salt; Cis-dichloroammine Platinum (II); Cis-platinum; (SP-4-2)-Diamminedichloroplatinum; Platinum; CDDP; Cis-platinum II Diamine Dichloride; DDP; Cismaplat; Peyrone's Chloride; Platinoxan; Platinum, Diaminedichloro-, cis- (8CI); Cisplatinum; Cis-diamminedichloridoplatinum; Cis-diamminedichloro Platinum (II); Cysplatyna; Cis-platinous Diamine Dichloride; Cis-diamminedichloroplatinum;
NCIt related terms : Platiblastin; Platinol;
NCIt definition : An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic
activity. Cisplatin forms highly reactive, charged, platinum complexes which bind
to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand
DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis
and cell growth inhibition.;
Alternative definition : NCI-GLOSS: A drug used to treat many types of cancer. Cisplatin contains the metal
platinum. It kills cancer cells by damaging their DNA and stopping them from dividing.
Cisplatin is a type of alkylating agent.;
UNII : Q20Q21Q62J;
InChIKey : LXZZYRPGZAFOLE-UHFFFAOYSA-L;
CAS number : 15663-27-1;
Drug name : Platiblastin; Blastolem; Platosin; Platinol-AQ; Citoplatino; Neoplatin; Platinol; Platamine; Platistin; Briplatin; Abiplatin; Citosin; Platinol-AQ VHA Plus; Cisplatyl; Metaplatin; Plastistil; Placis; Platiblastin-S; Lederplatin; Platinol- AQ; Platinex; Platiran;
Chemical formula : 2Cl.Pt.2H3N;
NSC code : 119875;
ChEBI ID : CHEBI:27899;
Codes from synonyms : 00524; CDR0000045230; NSC0119875; 105;
Origin ID : C376;
UMLS CUI : C0008838;
Automatic exact mappings (from CISMeF team)
- False automatic mappings
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- Validated automatic mappings to NTBT
- concept_is_in_subset
- is_component_of_chemotherapy_regimen
https://www.cochrane.org/fr/CD014805/BREASTCA_chimiotherapie-contenant-du-platine-pour-les-femmes-avant-ou-apres-une-intervention-chirurgicale
2023
United Kingdom
review of literature
french abstract
Negative Lymph Node
FGFR1 Gene Mutation Negative
GNA11 Gene Mutation Negative
Pharmacotherapy
ERBB2 Gene Amplification Negative
PAS Negative
Cancer Intervention
ERG Gene Rearrangement Negative
Hepatitis B Virus Core Antibody Negative
neoplasm staging
KIT Negative
women
Woman
Hepatitis B Surface Antibody Negative
platinum, nos
SDHB Negative
neoplasm, malignant
Cisplatin
ANO1 Negative
Polypodium leucotomos Extract
ERBB2 Gene Mutation Negative
platinum
Unmethylated MGMT Gene Promoter
FGFR3 Gene Mutation Negative
Lack of Expression of PD-L1
procedural approach, nos
Contain
FGFR2 Gene Mutation Negative
HRAS Gene Mutation Negative
BAP1 Gene Mutation Negative
Carboplatin
NRAS Gene Mutation Negative
operative procedure, nos
Progesterone Receptor Negative
Chemotherapy
Wnt Negative
KRAS Gene Mutation Negative
triplets
FGFR3 Gene Rearrangement Negative
CDKN2A-p16 Negative
Human Immunodeficiency Virus Negative
PAX8 Gene Rearrangement Negative
Drug Therapy
During or After
CTNNB1 Gene Mutation Negative
FGFR2 Gene Rearrangement Negative
GNAQ Gene Mutation Negative
early
RET Gene Rearrangement Negative
Status Post
Negative Number
ATRX Gene Mutation Negative
Have Not Tried It
1p/19q Codeletion Negative
ESR2 Negative
breast cancer
Surgical Procedure
Epstein-Barr Virus Negative
chemotherapy
10q23/PTEN Locus Deletion Negative
Platinum
SDHA Negative
triple negative breast neoplasms
Negative Charge
Hepatitis B Virus Surface Antigen Negative
TERT Promoter Mutation Negative
BRAF Gene Mutation Negative
Early Stage Breast Carcinoma
ETV Gene Rearrangement Negative
surgical procedures, operative
IDH Family Wildtype
chemotherapy, nos
Succimer
Platinum
CDH1 Gene Mutation Negative
---
